by TractManager | Feb 28, 2022 | Emerging Technology Report
Bardoxolone is an investigational oral nuclear factor erythroid-derived 2-related factor 2 (Nrf2) activator proposed to slow the progression of kidney disease in patients aged ≥ 12 years with chronic kidney disease caused by Alport Syndrome. If you have a Hayes login,...
by TractManager | Feb 25, 2022 | Health Technology Assessment
Focus of the Report: This Health Technology Assessment focuses on the use of mechanochemical endovenous ablation (MOCA), a nonthermal type of ablation for treatment of varicose veins, with the ClariVein infusion catheter (Merit Medical Systems Inc.).Technology...
by TractManager | Feb 23, 2022 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of powered microprocessor prosthetic ankles for patients with transtibial amputation, compared with nonpowered...
by TractManager | Feb 23, 2022 | Clinical Utility Evaluation
This report evaluates the clinical utility of cell-free DNA (cfDNA) (formerly NIPS, NIPT) screening for fetal chromosomal copy number variants (CNVs) in women with singleton or twin pregnancies.If you have a Hayes login, click here to view the full report on the...
by TractManager | Feb 16, 2022 | Evolving Evidence Review
This report addresses whether full-text clinical studies, systematic reviews, and clinical practice guidelines and position statements support the use of cryoneurolysis/cryoanalgesia via the iovera° system for postoperative knee pain following total knee arthroplasty...
Recent Comments